Samsara BioCapital, LLC
PALO ALTO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.05B2026 Q3
Positions27
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.87.9%
What Changed This Quarter?
Top Holdings
SRRK
Scholar Rock
31.7%
MLYS
Mineralys Therapeutics
14.0%
SEPN
Septerna
11.4%
ALMR
Alamar Biosciences
8.0%
SGP
SpyGlass Pharma
5.2%
ALMS
Alumis
5.1%
NGNE
Neurogene
4.9%
KLRS
Kalaris Therapeutics
3.5%
New / Increased
4 new · 3 increased
PMVPNEW
PMV Pharmaceuticals
1.1%
OBXNEW
Obsidian Therapeutics
1.1%
Tcgx Acquisit…NEW
TCGX Acquisition
0.1%
Gossamer BioNEW
Gossamer Bio
0.1%
ALMS
Alumis
5.1%
+14.0%
NGNE
Neurogene
4.9%
+8.7%
VTVT
VTV Therapeutics
1.0%
+18.8%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.